Form 4: OrbiMed Advisors Sells 39,300 Shares of Passage Bio, Inc. (PASG)
SEC Form 4 Filing
OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., disposed of 39,300 shares of common stock at an average price of $0.71 per share on September 19, 2024.
Summary
- On September 19, 2024, OrbiMed Advisors LLC sold 39,300 shares of Passage Bio, Inc. (PASG) common stock.
- The shares were sold at a weighted average price of $0.71, with individual prices ranging from $0.70 to $0.73.
- Following the transaction, OrbiMed Advisors, through its affiliates, indirectly beneficially owns 7,794,569 shares of Passage Bio.
- OrbiMed Advisors disclaims beneficial ownership of these securities except to the extent of its pecuniary interest.
Sentiment
Score: 5
Explanation: Neutral sentiment. The document simply reports a transaction. The sale of shares by a major holder could be seen as slightly negative, but it's a common occurrence.
Negatives
- OrbiMed Advisors, a major shareholder, has reduced its holdings in Passage Bio by selling 39,300 shares.
Risks
- Continued selling pressure from major shareholders like OrbiMed could negatively impact Passage Bio's stock price.
Management Comments
- Carl L. Gordon, Member of OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, signed the Form 4 filing.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell shares. This filing indicates a change in OrbiMed's position in Passage Bio.
Comparison to Industry Standards
- It's common for investment firms like OrbiMed to periodically adjust their holdings in portfolio companies.
- Similar transactions are regularly seen with other biotech firms and their major investors, such as those involving Baker Bros. Advisors or RA Capital Management.
Stakeholder Impact
- Shareholders may react to the news of OrbiMed's share sale, potentially impacting the stock price.
- The sale could influence investor sentiment regarding Passage Bio's prospects.
Key Dates
| Date | Description |
|---|---|
| 09/19/2024 | Date of transaction: OrbiMed Advisors sold 39,300 shares of Passage Bio. |
| 09/23/2024 | Date of signature for the Form 4 filing by Carl L. Gordon, Member of OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.